Clinical evidence from patients with central AVP deficiency showed that desmopressin administration increases insulin-like growth factor-binding protein 1 (IGFBP-1) without altering IGF-1, glucose, insulin, glucagon or cortisol levels [34]. The gene discussed is IGFBP1; the disease is neurohypophyseal diabetes insipidus.